Welcome to
Endpoints News’
manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
Merck has received
a $30 million strategic fund from the state of Delaware’s Division of Small Business, a state spokesperson told Endpoints. And, Merck is considering building a new commercialization and launch facility in Delaware, the pharma company said.
Granules India has
entered
the peptide market by buying Swiss CDMO Senn Chemicals, the company said Friday. The acquisition, which is expected to close in the first half of 2025, will give Granules capabilities in making GLP-1 drugs and other peptides. The acquisition is worth Swiss franc 20 million ($22.3 million), the company told Endpoints.
Bavarian Nordic has
partnered
with India-based Biological E to scale up manufacturing of Bavarian’s chikungunya vaccine in low- and middle-income countries, according to a Tuesday press release. Bavarian will transfer the manufacturing technology of the vaccine to Biological E.
WuXi XDC has
signed
an expanded Memorandum of Understanding with LigaChem Biosciences. WuXi will provide its ADC discovery and manufacturing services for LigaChem’s multiple projects, the companies said Tuesday.
PanTera will
supply
the radioisotope actinium-225 to SK Biopharmaceuticals to use in its radiopharma therapies, the companies said Tuesday.
The European Union is
investing
€8.9 million ($9.3 million) to boost local manufacturing in the Caribbean, according to a Monday release. The funding will be used to improve the quality and accessibility of medicines in the region.
Hims & Hers Health
acquired
a manufacturing facility to make peptide-based drugs, the company said Friday. No financial terms were disclosed. The company’s stock fell last week after the FDA announced
shortages of Ozempic and Wegovy have been resolved
, a blow to Hims’ compounding business.
The Canadian government is
buying
500,000 doses of GSK’s bird flu vaccine, according to a Feb. 19 press release. Around 60% of the doses will be rolled out immediately and 40% will be placed in its national stockpile.
CDMO OneSource Specialty Pharma is
aiming
for a revenue of $400 million in the next three to four years and will expand its capacity to produce over 200 million cartridges like injections in the next few years, the CEO said in an interview with
CNBC
on Tuesday.
Recipharm has
opened
a new facility in Zwickau, Germany — dubbed its “Pilot Scale Development Centre” — which will be used to manufacture tablets and hard capsules, the CDMO said Thursday. The site was
announced
in October last year.
Gerresheimer’s glass packaging business
saw
some
destocking
from customers throughout 2024, with sales decreasing to €899 million ($942 million) from €927 million ($972 million) reported in 2023, the company said Wednesday. The company has cut its overall 2025 forecast to between 3% and 5%, down from the original 7% to 10% range.